Acacia Pharma has posted positive results from its Phase II study of APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients. The study showed that APD515 hit its primary endpoint, significantly reducing the symptoms of dry mouth compared to placebo. APD515 is an optimised oromucosal (liquid) formulation of a currently marketed muscarinic agonist for the completely new, patent-protected use of treatment of xerostomia. The randomised, double-blind, placebo-controlled, cros...